Similarly, Yip and Yim [7], who focused on the role of IL-6R inhibitors in the management of RA, reported that sarilumab demonstrates significant improvements in ACR20 response rates, physical function (measured by the HAQ-DI scores), and remission rates (assessed by the DAS28 and Clinical Disease Activity Index scores) compared to placebo. The gene discussed is IL6R; the disease is rheumatoid arthritis.